KalVista Pharmaceuticals (KALV)
(Delayed Data from NSDQ)
$10.49 USD
-0.51 (-4.64%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $10.52 +0.03 (0.29%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for KalVista Pharmaceuticals, Inc falls in the month of April.
All items in Millions except Per Share data.
4/30/2024 | 4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 210 | 149 | 166 | 249 | 68 |
Receivables | 8 | 17 | 14 | 10 | 17 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 7 | 6 | 13 | 5 | 4 |
Total Current Assets | 226 | 172 | 194 | 264 | 89 |
Net Property & Equipment | 2 | 3 | 2 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 0 | 0 | 0 | 0 |
Total Assets | 235 | 183 | 204 | 272 | 93 |
Liabilities & Shareholders Equity | 4/30/2024 | 4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 9 | 5 | 4 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 12 | 9 | 7 | 7 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 23 | 15 | 12 | 10 | 8 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 29 | 22 | 19 | 15 | 9 |
Shareholders Equity | 4/30/2024 | 4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 680 | 507 | 439 | 426 | 207 |
Retained Earnings | -470 | -343 | -250 | -168 | -122 |
Other Equity | -3 | -3 | -4 | -1 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 207 | 161 | 185 | 257 | 84 |
Total Liabilities & Shareholder's Equity | 235 | 183 | 204 | 272 | 93 |
Total Common Equity | 207 | 161 | 185 | 257 | 84 |
Shares Outstanding | 42.50 | 34.10 | 24.50 | 24.40 | 17.80 |
Book Value Per Share | 4.86 | 4.72 | 7.55 | 10.54 | 4.71 |
Fiscal Year End for KalVista Pharmaceuticals, Inc falls in the month of April.
All items in Millions except Per Share data.
7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 174 | 210 | 76 | 103 | 123 |
Receivables | 10 | 8 | 23 | 20 | 19 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 7 | 7 | 6 | 5 | 8 |
Total Current Assets | 192 | 226 | 104 | 129 | 150 |
Net Property & Equipment | 2 | 2 | 2 | 3 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 0 | 0 | 0 |
Total Assets | 200 | 235 | 114 | 139 | 160 |
Liabilities & Shareholders Equity | 7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 11 | 9 | 3 | 5 | 5 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 10 | 12 | 15 | 12 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 22 | 23 | 19 | 18 | 14 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 27 | 29 | 25 | 24 | 21 |
Shareholders Equity | 7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 686 | 680 | 517 | 514 | 511 |
Retained Earnings | -510 | -470 | -425 | -396 | -368 |
Other Equity | -3 | -3 | -3 | -3 | -3 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 173 | 207 | 89 | 114 | 139 |
Total Liabilities & Shareholder's Equity | 200 | 235 | 114 | 139 | 160 |
Total Common Equity | 173 | 207 | 89 | 114 | 139 |
Shares Outstanding | 43.20 | 42.50 | 34.50 | 34.40 | 34.20 |
Book Value Per Share | 4.00 | 4.86 | 2.57 | 3.33 | 4.07 |